| BASEL,
Switzerland--(BUSINESS WIRE)--June 27, 2005--Jain PharmaBiotech
has announced the publication of a New Report "Cardiovascular Drug Delivery - Technologies,
Markets & Companies".
Drug delivery to the cardiovascular system is approached
at three levels: (1) routes of drug delivery; (2) formulations;
and (3) applications to various diseases. Cell and gene therapies,
including antisense and RNA interference, are described in
detail as they are the most innovative methods of delivery
of therapeutics. Various methods of improving systemic administration
of drugs for targeted action in cardiovascular disorders
are described including use of nanotechnology. A full chapter
is devoted to drug-eluting stents used for treatment of restenosis
following stenting of coronary arteries.
Cardiovascular drug delivery markets are estimated for the
years 2005 to 2015 on the basis of epidemiology and total
markets for cardiovascular therapeutics. The estimates take
into consideration the anticipated advances and availability
of various technologies, particularly drug delivery devices
in the future. Markets for drug-eluting stents are calculated
separately. Selected 52 companies that either develop technologies
for drug delivery to the cardiovascular system or products
using drug delivery are profiled and collaborations between
companies are tabulated. Further details about the report
can be viewed at the following web site:
http://pharmabiotech.ch/reports/cardiovascular/
This reports joins a series of drug delivery reports by
Jain PharmaBiotech including transdermal drug delivery, drug
delivery in cancer and drug delivery for CNS disorders.
About Jain PharmaBiotech
Jain PharmaBiotech is a research and documentation company
that provides consulting services for biotechnology and pharmaceutical
industries. Forty-four reports have been prepared at the
Company during the past 10 years, many of which were printed
and marketed by other publishers. Sixteen of these reports
are now published by Jain PharmaBiotech in house and regularly
updated - a unique feature not available in competing reports.
Each report contains numerous tables, figures and references
to the literature. The detailed table of contents and summary
of each report is posted on the web site. The customer gets
up-to-date information at the time of purchase and has the
option to by subsequent editions at discounted prices. More
reports in this style are in preparation.
Contact: Prof. K. K. Jain MD, FFPM CEO, Jain
PharmaBiotech Blaesiring 7 CH-4057 Basel, Switzerland Tel/Fax:
+4161 692 44 61 Mobile: +41(0)79-685 6337 Email: jain@pharmabiotech.ch Web: http://pharmabiotech.ch/
Source: Jain PharmaBiotech
|
